Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progress in the rational design of an AIDS vaccine.

Literature DB >> 21893538

Progress in the rational design of an AIDS vaccine.

Gary J Nabel¹, Peter D Kwong, John R Mascola.

Abstract

Human immunodeficiency virus-1 (HIV-1) has a high degree of genetic and antigenic diversity that has impeded the development of an effective vaccine using traditional methods. We are attempting to develop an AIDS vaccine by employing strategies that include structural biology and computational modelling, in an effort to develop immunogens capable of eliciting neutralizing antibodies of the requisite breadth and potency against circulating strains of HIV-1.

Entities: Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21893538 PMCID： PMC3146778 DOI： 10.1098/rstb.2011.0096

Source DB: PubMed Journal: Philos Trans R Soc Lond B Biol Sci ISSN： 0962-8436 Impact factor: 6.237

34 in total

1. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors: Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal: J Virol Date: 2010-06-10 Impact factor: 5.103

Review 2. Antibodies, viruses and vaccines.

Authors: Dennis R Burton
Journal: Nat Rev Immunol Date: 2002-09 Impact factor: 53.106

3. Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors: David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal: Curr Opin HIV AIDS Date: 2007-05 Impact factor: 4.283

Review 4. Vaccines: correlates of vaccine-induced immunity.

Authors: Stanley A Plotkin
Journal: Clin Infect Dis Date: 2008-08-01 Impact factor: 9.079

5. Philosophy of science. The coordinates of truth.

Authors: Gary J Nabel
Journal: Science Date: 2009-10-02 Impact factor: 47.728

Review 6. The role of antibodies in HIV vaccines.

Authors: John R Mascola; David C Montefiori
Journal: Annu Rev Immunol Date: 2010 Impact factor: 28.527

7. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors: Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal: J Infect Dis Date: 2006-11-03 Impact factor: 5.226

8. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors: Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal: J Virol Date: 2003-10 Impact factor: 5.103

9. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors: Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal: Science Date: 2009-11-20 Impact factor: 47.728

10. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors: Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal: Nature Date: 2009-03-15 Impact factor: 49.962

33 in total

Review 1. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors: Peter D Kwong; John R Mascola; Gary J Nabel
Journal: Cold Spring Harb Perspect Med Date: 2011-09 Impact factor: 6.915

Review 2. Viral quasispecies evolution.

Authors: Esteban Domingo; Julie Sheldon; Celia Perales
Journal: Microbiol Mol Biol Rev Date: 2012-06 Impact factor: 11.056

Review 3. Minireview: applied structural bioinformatics in proteomics.

Authors: Yee Siew Choong; Gee Jun Tye; Theam Soon Lim
Journal: Protein J Date: 2013-10 Impact factor: 2.371

4. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

Authors: Anthony P West; Ron Diskin; Michel C Nussenzweig; Pamela J Bjorkman
Journal: Proc Natl Acad Sci U S A Date: 2012-06-27 Impact factor: 11.205

5. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.

Authors: Louise Scharf; Johannes F Scheid; Jeong Hyun Lee; Anthony P West; Courtney Chen; Han Gao; Priyanthi N P Gnanapragasam; René Mares; Michael S Seaman; Andrew B Ward; Michel C Nussenzweig; Pamela J Bjorkman
Journal: Cell Rep Date: 2014-04-24 Impact factor: 9.423

Review 9. Designing tomorrow's vaccines.

Authors: Gary J Nabel
Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245

10. Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors: Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal: Vaccine Date: 2013-11-23 Impact factor: 3.641